Valneva SE of France has appointed Hanneke Schuitemaker as chief scientific officer. Dr Schuitemaker will focus on accelerating the company’s pre-clinical and translational R&D for the advancement of Valneva’s vaccine pipeline which includes candidates against Lyme disease and the Zika virus. She brings more than 20 years of experience in vaccine discovery and development, serving formerly as global head of viral vaccine discovery and translational medicine at Johnson & Johnson Inc.
Valneva announced the appointment on 21 May 2024
Copyright 2024 Evernow Publishing Ltd
